VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
Titel:
VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
Auteur:
Le Cesne, A. Schiffler, C. Bouche, O. Brahmi, M. Duffaud, F. Toulmonde, M. Landi, B. Lahlou, W. Pannier, D. Bompas, E. Bertucci, F. Chaigneau, L. Collard, O. Pracht, M. Adenis, A. Ray-Coquard, I. Metzger, S. Chabaud, S. Perol, D. Blay, J-Y.